CytomX Therapeutics 

CytomX Therapeutics, Inc. (CTMX) announced that it will report first quarter 2024 results and provide an initial CX-904 Phase 1a dose escalation update on Wednesday, May 8, 2024, after the close of U.S. markets.

Following the announcement the company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT.  Participants may access the . . .